$9m in ARC grants released
Tuesday, 03 June, 2003
Some of Australia's best-known biotechs -- including Biota, Gradipore, Amrad, Proteome Systems, Nanomics, Starpharma and PanVax -- will benefit from the latest round of Australian Research Council linkage grants.
Life science projects picked up $9 million of the total $47.5 million on offer.
Linkage grants support the development of strategic research alliances with industry. Companies provide $1.64 for every $1 spent by the Commonwealth.
Prof Alan Johnson, executive director of biological sciences and biotechnology for the ARC, said the linkage scheme had been a success, particularly since the move to offer two rounds of funding per year. "Successful recipients can get going faster," he said.
Big pharma also takes part -- Novartis Animal Health and GlaxoSmithKline are industry partners this round. And industry organisation AusBiotech is also a participant in two grants looking at commercialisation strategies and comparisons between biotechnology, nanotechnology and the information technology industries.
Immune cell boost could enable lasting vaccine protection
A research team has found a promising new way to enhance the effectiveness of vaccines by tapping...
Genes influence when babies start walking
Genetics accounts for about a quarter of the differences in when children take their first steps,...
Novel glycopeptide antibiotic candidate shows promise
Researchers have discovered a new type of glycopeptide antibiotic known as saarvienin A, found to...
